Sangamo BioSciences, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Sangamo BioSciences, Inc. – Product Pipeline Review – 2016’, provides an overview of the Sangamo BioSciences, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sangamo BioSciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sangamo BioSciences, Inc.

The report provides overview of Sangamo BioSciences, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sangamo BioSciences, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sangamo BioSciences, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sangamo BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sangamo BioSciences, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sangamo BioSciences, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Sangamo BioSciences, Inc. Snapshot 6

Sangamo BioSciences, Inc. Overview 6

Key Information 6

Key Facts 6

Sangamo BioSciences, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Sangamo BioSciences, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Sangamo BioSciences, Inc. - Pipeline Products Glance 12

Sangamo BioSciences, Inc. - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Sangamo BioSciences, Inc. - Early Stage Pipeline Products 14

IND/CTA Filed Products/Combination Treatment Modalities 14

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Sangamo BioSciences, Inc. - Drug Profiles 17

SB-728T 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

SB-728HSPC 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

SB-FIX 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

SB-318 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Stem Cell Therapy for Beta Thalassemia 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Gene Therapy for Sickle Cell Disease 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Gene Therapy for X-Linked SCID 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Gene Therapy to Active Pulmonary Surfactant-Associated Protein B for Lung Diseases 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

SB-913 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SB-FVIII 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SBLSD-3 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SBLSD-4 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Gene Therapy for Monogenic Diseases 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Sangamo BioSciences, Inc. - Pipeline Analysis 34

Sangamo BioSciences, Inc. - Pipeline Products by Target 34

Sangamo BioSciences, Inc. - Pipeline Products by Route of Administration 35

Sangamo BioSciences, Inc. - Pipeline Products by Molecule Type 36

Sangamo BioSciences, Inc. - Pipeline Products by Mechanism of Action 37

Sangamo BioSciences, Inc. - Recent Pipeline Updates 38

Sangamo BioSciences, Inc. - Dormant Projects 49

Sangamo BioSciences, Inc. - Discontinued Pipeline Products 50

Discontinued Pipeline Product Profiles 50

CERE-110 50

CERE-120 50

SB-509 50

Sangamo BioSciences, Inc. - Company Statement 51

Sangamo BioSciences, Inc. - Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Sangamo BioSciences, Inc., Key Information 6

Sangamo BioSciences, Inc., Key Facts 6

Sangamo BioSciences, Inc. – Pipeline by Indication, 2016 8

Sangamo BioSciences, Inc. – Pipeline by Stage of Development, 2016 10

Sangamo BioSciences, Inc. – Monotherapy Products in Pipeline, 2016 11

Sangamo BioSciences, Inc. – Phase II, 2016 12

Sangamo BioSciences, Inc. – Phase I, 2016 13

Sangamo BioSciences, Inc. – IND/CTA Filed, 2016 14

Sangamo BioSciences, Inc. – Preclinical, 2016 15

Sangamo BioSciences, Inc. – Discovery, 2016 16

Sangamo BioSciences, Inc. – Pipeline by Target, 2016 34

Sangamo BioSciences, Inc. – Pipeline by Route of Administration, 2016 35

Sangamo BioSciences, Inc. – Pipeline by Molecule Type, 2016 36

Sangamo BioSciences, Inc. – Pipeline Products by Mechanism of Action, 2016 37

Sangamo BioSciences, Inc. – Recent Pipeline Updates, 2016 38

Sangamo BioSciences, Inc. – Dormant Developmental Projects,2016 49

Sangamo BioSciences, Inc. – Discontinued Pipeline Products, 2016 50

Sangamo BioSciences, Inc., Subsidiaries 53

List of Figures

List of Figures

Sangamo BioSciences, Inc. – Pipeline by Top 10 Indication, 2016 8

Sangamo BioSciences, Inc. – Pipeline by Stage of Development, 2016 10

Sangamo BioSciences, Inc. – Monotherapy Products in Pipeline, 2016 11

Sangamo BioSciences, Inc. – Pipeline by Target, 2016 34

Sangamo BioSciences, Inc. – Pipeline by Route of Administration, 2016 35

Sangamo BioSciences, Inc. – Pipeline by Molecule Type, 2016 36

Sangamo BioSciences, Inc. – Pipeline Products by Mechanism of Action, 2016 37

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports